Logo image of KNTE

KINNATE BIOPHARMA INC (KNTE) Stock Fundamental Analysis

NASDAQ:KNTE - Nasdaq - US49705R1059 - Common Stock - Currency: USD

2.65  -0.01 (-0.38%)

After market: 2.65 0 (0%)

Fundamental Rating

2

Taking everything into account, KNTE scores 2 out of 10 in our fundamental rating. KNTE was compared to 558 industry peers in the Biotechnology industry. KNTE has a great financial health rating, but its profitability evaluates not so good. KNTE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KNTE has reported negative net income.
KNTE had a negative operating cash flow in the past year.
In the past 5 years KNTE always reported negative net income.
KNTE had a negative operating cash flow in each of the past 5 years.
KNTE Yearly Net Income VS EBIT VS OCF VS FCFKNTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -64.89%, KNTE is not doing good in the industry: 62.35% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -70.70%, KNTE is in line with its industry, outperforming 56.22% of the companies in the same industry.
Industry RankSector Rank
ROA -64.89%
ROE -70.7%
ROIC N/A
ROA(3y)-43.69%
ROA(5y)-30.56%
ROE(3y)-50.27%
ROE(5y)-34.61%
ROIC(3y)N/A
ROIC(5y)N/A
KNTE Yearly ROA, ROE, ROICKNTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

KNTE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KNTE Yearly Profit, Operating, Gross MarginsKNTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, KNTE has more shares outstanding
Compared to 5 years ago, KNTE has more shares outstanding
KNTE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KNTE Yearly Shares OutstandingKNTE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
KNTE Yearly Total Debt VS Total AssetsKNTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 1.00, we must say that KNTE is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of KNTE (1.00) is better than 64.57% of its industry peers.
KNTE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1
ROIC/WACCN/A
WACCN/A
KNTE Yearly LT Debt VS Equity VS FCFKNTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 13.19 indicates that KNTE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 13.19, KNTE belongs to the top of the industry, outperforming 86.88% of the companies in the same industry.
A Quick Ratio of 13.19 indicates that KNTE has no problem at all paying its short term obligations.
The Quick ratio of KNTE (13.19) is better than 87.05% of its industry peers.
Industry RankSector Rank
Current Ratio 13.19
Quick Ratio 13.19
KNTE Yearly Current Assets VS Current LiabilitesKNTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

KNTE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.68%, which is quite good.
EPS 1Y (TTM)8.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KNTE will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.70% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y47.95%
EPS Next 2Y28.83%
EPS Next 3Y13.35%
EPS Next 5Y13.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KNTE Yearly Revenue VS EstimatesKNTE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2027 2028 2029 2030 50M 100M 150M 200M 250M
KNTE Yearly EPS VS EstimatesKNTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KNTE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KNTE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KNTE Price Earnings VS Forward Price EarningsKNTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KNTE Per share dataKNTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

KNTE's earnings are expected to grow with 13.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.83%
EPS Next 3Y13.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KNTE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KINNATE BIOPHARMA INC

NASDAQ:KNTE (4/2/2024, 8:25:40 PM)

After market: 2.65 0 (0%)

2.65

-0.01 (-0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2024-03-28/amc
Earnings (Next)05-09 2024-05-09/amc
Inst Owners0.91%
Inst Owner Change0%
Ins Owners6.99%
Ins Owner Change0%
Market Cap125.00M
Analysts78
Price Target2.41 (-9.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.27%
Min EPS beat(2)5.59%
Max EPS beat(2)16.95%
EPS beat(4)4
Avg EPS beat(4)8.9%
Min EPS beat(4)1.96%
Max EPS beat(4)16.95%
EPS beat(8)7
Avg EPS beat(8)3.8%
EPS beat(12)7
Avg EPS beat(12)0.57%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.35%
PT rev (3m)-12.47%
EPS NQ rev (1m)1.14%
EPS NQ rev (3m)5.3%
EPS NY rev (1m)0%
EPS NY rev (3m)9.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-2.42
EYN/A
EPS(NY)-1.26
Fwd EYN/A
FCF(TTM)-2.12
FCFYN/A
OCF(TTM)-2.12
OCFYN/A
SpS0
BVpS3.38
TBVpS3.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.89%
ROE -70.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.69%
ROA(5y)-30.56%
ROE(3y)-50.27%
ROE(5y)-34.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.19
Quick Ratio 13.19
Altman-Z 1
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)365%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y47.95%
EPS Next 2Y28.83%
EPS Next 3Y13.35%
EPS Next 5Y13.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.09%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.37%
OCF growth 3YN/A
OCF growth 5YN/A